UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1258-7
Program Prior Authorization/Notification
Medications Galafold® (migalastat)
P&T Approval Date 9/2018, 10/2019, 10/2020, 10/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Galafold (migalastat) is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone indicated
for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase
alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial
capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication
may be contingent upon verification and description of clinical benefit in confirmatory trials.
2. Coverage Criteriaa:
A. Initial Authorization
1. Galafold will be approved based on all of the following criteria:
a. Diagnosis of Fabry disease
-AND-
b. Patient has an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data
-AND-
c. Patient is not receiving Galafold in combination with Fabrazyme (agalsidase beta) or Elfabrio
(pegunigalsidase alfa-iwxj)
Authorization will be issued for 12 months.
B. Reauthorization
1. Galafold will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Galafold therapy
-AND-
b. Patient is not receiving Galafold in combination with Fabrazyme (agalsidase beta) or Elfabrio
(pegunigalsidase alfa-iwxj)
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services, Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Galafold [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; June 2024.
Program Prior Authorization/Notification – Galafold (migalastat)
Change Control
9/2018 New program.
10/2019 Annual review with no changes to clinical coverage criteria. Updated
reference.
10/2020 Annual review. No change to clinical coverage criteria. Reauthorization
changed to 12 months. Reference updated.
10/2021 Annual review with no change to clinical coverage criteria. Updated reference.
10/2022 Annual review with no change to clinical coverage criteria. Added state
mandate footnote.
10/2023 Annual review. Added Elfabrio as a drug to not be used in combination.
Updated reference.
10/2024 Annual review with no change to clinical coverage criteria. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2